RSV vaccine uptake will start slower than shingles shot: GSK CEO
By A Mystery Man Writer
Description
GSK crushed Pfizer in first round of RSV vaccine showdown
GSK's RSV vaccine bolsters bottom line, company raises full-year guidance
GSK crushed Pfizer in first round of RSV vaccine showdown
RSV vaccine: CDC panel recommends Pfizer, GSK shots for adults over 60
GSK CEO Emma Walmsley On RSV Vaccines
424B4
RSV vaccine uptake will start slower than shingles shot: GSK CEO
SEC Filing
GSK nabs highly anticipated approval for RSV vaccine Arexvy
from
per adult (price varies by group size)